Table 5 Subgroup analysis. Comparison of the survival after dose reduction versus full dosage in different subgroups analyzed by Kaplan-Meier procedure and Log-Rank test (Chemotherapy (CTX))
Dosage reduction | Log-rank | |||
|---|---|---|---|---|
Yes (≤ 80%) | No (100%) | |||
Mean (Median) survival in months | p-value | |||
Age | < 65 | 22.0 (14.6) | 17.1 (12.0) | .170 |
≥65 | 18.8 (14.9) | 21.2 (15.8) | .764 | |
Sex | Male | 23.5 (16.0) | 18.6 (14.9) | .339 |
Female | 17.2 (13.1) | 17.4 (12.7) | .170 | |
T stage | T3 | 27.8 (26.4) | 25.8 (14.9) | .525 |
T4 | 15.6 (13.8) | 14.1 (12.7) | .960 | |
Tx | 24.3 (10.4) | 14.1 (7.7) | .273 | |
N stage | N0 | 25.9 (23.6) | 30.5 (14.9) | .851 |
N1 | 20.7 (13.9) | 24.1 (12.3) | .669 | |
N2 | 21.3 (26.4) | 13.3 (16.7) | .024 | |
Nx | 20.4 (16.0) | 13.2 (7.7) | .294 | |
Grading | G2 | 24.1 (17.8) | 22.0 (16.1) | .570 |
G3 | 17.5 (14.5) | 10.6 (10.4) | .062 | |
Gx | 26.8 (26.8) | 25.5 (3.0) | .808 | |
L stage | L0 | 19.7 (17.8) | 30.7 (21.0) | .541 |
L1 | 23.3 (13.9) | 16.9 (17.5) | .485 | |
Lx | 18.1 (14.8) | 16.3 (12.0) | .561 | |
V stage | V0 | 28.8 (23.6) | 26.9 (21.0) | .828 |
V1 | 20.3 (13.9) | 15.7 (16.7) | .311 | |
Vx | 16.9 (14.5) | 15.9 (11.8) | .671 | |
Charlson Score for Comorbidities | 6 | 20.6 (14.8) | 19.6 (12.0) | .424 |
7–10 | 23.3 (15.0) | 19.6 (16.1) | .632 | |
Oncological resection/Surgery | Yes | 22.1 (14.9) | 23.8 (17.5) | .997 |
No | 19.6 (12.9) | 12.9 (7.6) | .301 | |
No. of CTX lines | 1 | 10.1 (10.4) | 8.4 (3.0) | .565 |
2 | 23.1 (17.9) | 23.5 (15.8) | .896 | |
3 | 24.7 (23.6) | 16.6 (12.3) | .238 | |
Biological CTX | Yes | 29.4 (26.8) | 23.5 (11.8) | .371 |
No | 13.2 (13.1) | 14.6 (14.9) | .823 | |
CTX regimen sequence | FOLFOX- > FOLFIRI | 22.0 (20.2) | 26.5 (17.5) | .425 |
FOLFIRI- > FOLFOX | 12.3 (12.3) | 16.4 (14.9) | .631 | |
FOLFOX | 9.7 (12.9) | 7.7 (3.6) | .829 | |
FOLFIRI | 62.3 (90.7) | 13.0 (3.9) | .300 | |